Clinical validation for LOXO-101 against TRK fusion cancer
The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a ...
Jul 28, 2015
0
13